![](/img/cover-not-exists.png)
Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort
Welzel, Tania M, Petersen, Jörg, Herzer, Kerstin, Ferenci, Peter, Gschwantler, Michael, Wedemeyer, Heiner, Berg, Thomas, Spengler, Ulrich, Weiland, Ola, van der Valk, Marc, Rockstroh, Jürgen, Peck-RadVolume:
65
Language:
english
Journal:
Gut
DOI:
10.1136/gutjnl-2016-312444
Date:
November, 2016
File:
PDF, 1.17 MB
english, 2016